Eplerenone: Hypertension, heart failure and the importance of mineralocorticoid receptor blockade

Future Cardiology

Volumn 2, Issue 5, 2006, Pages 535-541

  Funder, John W ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Aldosterone; Cortisol; Eplerenone; Heart failure; Hypertension; Inflammation; Mineralocorticoid receptor; Reactive oxygen species; Spironolactone

Indexed keywords

ALDOSTERONE; ALDOSTERONE SYNTHASE INHIBITOR; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANRENOATE POTASSIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DROSPIRENONE; ENALAPRIL; EPLERENONE; FAD 286; FIBRINOLYTIC AGENT; HYDROCORTISONE; HYPERICUM PERFORATUM EXTRACT; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; OXYGENASE INHIBITOR; PLACEBO; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; RENIN INHIBITOR; SODIUM; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRIAMTERENE; UNCLASSIFIED DRUG;

ALDOSTERONE BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG DEGRADATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SOLUBILITY; DRUG STRUCTURE; ERECTILE DYSFUNCTION; ESSENTIAL HYPERTENSION; GYNECOMASTIA; HEART FAILURE; HEART INFARCTION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; MASTALGIA; MENSTRUATION DISORDER; NONHUMAN; PATHOPHYSIOLOGY; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM BLOOD LEVEL; TABLET;

EID: 33749539131     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/14796678.2.5.535     Document Type: Article

References (22)

1. Pitt B, Zannad F, Remme WJ et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med. 341(10), 709-717 (1999).
2. Pitt B, Remme W, Zannad F et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 348(14), 1309-1321 (2003).
3. Pitt B, Reichek N, Willenbrock R et al.: Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation 108(15), 1831-1838 (2003).
4. Young M, Moussa L, Dilley R, Funder JW: Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11 β-hydroxysteroid dehydrogenase inactivation. Endocrinology 144(3), 1121-1125 (2003).
5. Nagata K, Obata K, Xu J et al.: Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-renin, low-aldosterone hypertensive rats. Hypertension 47, 656-664 (2006).
6. Funder JW: Is aldosterone bad for the heart? Trends Endocrinol. Metab. 15, 139-142 (2004).
7. Funder JW: RALES, EPHESUS and redox. J. Steroid Biochem. Mol. Biol. 93, 121-125 (2005).
8. Juurlink DN, Mamdani MM, Lee DS et al.: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl. J. Med. 351(6), 543-551 (2004).
9. Flack JM, Oparil S, Pratt JH et al.: Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J. Am. Coll. Cardiol. 41(7), 1148-1155 (2003).
10. Weber MA: Clinical implications of aldosterone blockade. Am. Heart J. 144, S12-S18 (2002).
11. Sica DA: Eplerenone: a new aldosterone receptor antagonist - are the FDAs restrictions appropriate? J. Clin. Hyperten. 4(6) 441-445 (2002).
12. Levy D, Rocha R, Funder JW: Distinguishing the antihypertensive and electrolyte effects of eplerenone. J. Clin. Endocrinol. Metab. 89, 2736-2740 (2004).
13. Funder JW: Aldosterone-renin ratios in the context of primary care. J. Clin. Endocrinol. Metab. 89, 4219-4220 (2004).
14. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier CTL: Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31(2), 451-458 (1998).
15. Rocha R, Chander PN, Zuckerman A, Stier CT: Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 33(II), 232-237 (1999).
16. Young M, Head G, Funder J: Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am. J. Physiol. 269(4). E657-E662 (1995).
17. Rajagopalan S, Duquaine D, King S, Pitt B, Patel P: Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 105(18), 2212-2216 (2002).
18. Takai S, Jin D, Muramatsu M, Kirimura K, Sakonjo H, Miyazaki M: Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension 46(5), 1135-1139 (2005).
19. Funder JW: Mineralocorticoid receptors and cardiovascular damage: it's not just aldosterone. Hypertension 47(4), 634-635 (2006).
20. Rocha R, Martin-Berger C, Yang P, Scherrar R, Delyani J, McMahon E: Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 143, 4828-4836 (2002).
21. Rocha R, Rudolph A, Frierdich G et al.: Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am. J. Physiol. 283, H1803-H1810 (2002).
22. Young M, Fullerton M, Dilley R. Funder J: Mineralocorticoids, hypertension, and cardiac fibrosis. J. Clin. Invest. 93(6), 2578-2583 (1994).